biotech / news / / Firstpost
Tecentriq SC (atezolizumab) has been launched in India for treating certain types of lung cancer.
Tecentriq SC, a seven-minute subcutaneous cancer immunotherapy, has launched in India for specific lung cancers.
KEY POINTS
- This is the world's first subcutaneous immunotherapy for lung cancer, reducing administration time by 80 percent.
- Tecentriq SC uses Halozyme's technology to make skin tissue more porous for efficient drug absorption.
- Roche claims the new method can lower cancer care costs in India by up to 80 percent.
COMPANIES
Summarized by Newsio from Firstpost. How we summarize →